[New revision]: December 2023.
Docking Personnel": [Zhou Wen].
Global New Preparation Industry R&D Prospect and Special Investment Research Report 2023 2031
Chapter 1: Overview of the development of the novel formulation industry.
1.1 Overview of the new formulation industry.
1.1.1 Industry definition and scoping.
1.1.2 Classification of new preparation products.
1.3.2 Medicinal value for patients.
1.3.3 The low-cost value of new formulations and new drugs.
Chapter 2: Analysis of the development of the global novel formulation industry.
2.1 Analysis of the development of the global new preparation industry.
2.1.1 The development of the global pharmaceutical market.
2.1.2 Overview of the development of the global new preparation industry.
2.1.3 The market size of the global new preparation industry.
2.2 The market competition pattern of the global new preparation industry.
2.2.1 The competitive landscape of the global new formulation industry.
2.2.2 The main types of manufacturers of new preparations.
1) Generic drug manufacturers.
2) Patented drug manufacturers.
3) New preparation technology-based enterprises.
2.2.3 Analysis of key enterprises in the new preparation industry.
1) Pfizer Inc.
2) GlaxoSmithKline, UK.
3) Sanofi-Aventis of France.
4) Novartis AG of Switzerland.
5) Johnson & Johnson Pharmaceuticals.
6) AstraZeneca, United Kingdom, Sweden.
7) Abbott Laboratories of the United States.
8) Other drug development companies.
2.4 The development trend of the global new preparation industry.
2.4.1. Cooperation between patented drug companies and new preparation companies.
2.4.2 New preparation R&D intermediaries will spring up.
2.4.3 New formulations will become important for new drugs**.
Chapter 3: Analysis of the development environment of China's novel formulation industry.
3.1. Analysis of the industry policy environment.
3.1.1. Industry management system.
3.1.2. Policies related to industry development.
3.2. Analysis of industry demand environment.
3.2.1 Household consumption expenditure.
3.2.2 Total health costs.
3.2.3 Health care spending.
3.3. Industry R&D environment.
Chapter 4: Analysis of the development of China's new agent industry.
4.1 Analysis of the development of China's pharmaceutical industry.
4.1.1 Development status of China's pharmaceutical industry.
4.1.2 Market size of China's pharmaceutical industry.
4.1.3 Supply and demand analysis of China's pharmaceutical industry.
4.1.4 Drug R&D in China's pharmaceutical industry.
1) R&D investment in drugs.
2) The main body of drug research and development.
3) Drug R&D results.
4.1.5 Drug R&D model in China's pharmaceutical industry.
1) Independent research and development.
2) Drug R&D outsourcing CRO
3) Cooperate with professional bodies.
4) R&D strategic alliances.
5) Joint venture R&D.
4.3.5 Substitute Threats.
4.3.6 Summary of the competitive situation.
Chapter 5: Product Market Analysis of China's Novel Formulation Industry.
5.1 Market analysis of new formulations for oral administration.
5.1.1 Classification and advantages of new preparations for oral administration.
5.1.2 Application fields of new preparations for oral administration.
5.1.3 Oral administration: New formulations represent drugs.
5.1.4. Major manufacturers of new preparations for oral administration.
5.1.5 Market demand analysis of new oral administration preparations.
5.2 Market analysis of new formulations for injectable drug delivery.
5.2.1 Classification and advantages of new preparations for injection administration.
5.2.2 Application fields of new preparations for injection administration.
5.2.3 Injection administration: New formulations represent drugs.
Global New Preparation Industry R&D Prospect and Special Investment Research Report 2023 2031
5.4.4. The main manufacturer of new preparations for transdermal drug delivery.
5.4.5 Market demand analysis of new preparations for transdermal drug delivery.
Chapter 6: Analysis of the Technology Level of the Novel Formulation Industry.
6.1 Drug delivery system studies.
6.1.1 Drug delivery system concept.
6.1.2 Classification of drug delivery systems.
6.1.3 Research progress on drug delivery systems at home and abroad.
6.1.4 The gap between China's drug delivery system research and that of foreign countries.
6.2 Analysis of the development of sustained-release preparation technology.
6.2.1 Technical concept of sustained-release formulation.
6.2.2 Technical classification of sustained-release preparations.
6.2.3 Global development of sustained-release formulation technology.
6.2.4 The development of sustained-release preparation technology in China.
6.3 Analysis of the development of targeted preparation technology.
6.3.1 Targeted formulation technology concept.
6.3.2 Classification of targeted preparation technology.
6.3.3 The development of foreign targeted preparation technology.
6.3.4 The development status of targeted preparation technology in China.
1) Research history of targeted preparations in China.
6.5.3 Research progress on absorption promoters.
6.5.4 The development of mucosal drug delivery system technology in foreign countries.
6.5.5 The development of mucosal drug delivery system technology in China.
1) Research progress on mucosal drug delivery system technology in China.
2) Research progress on mucosal drug delivery system of traditional Chinese medicine.
6.6. Analysis of the development of other new preparation technologies.
6.6.1 Intelligent drug delivery system.
6.6.2 A new approach to the brain drug delivery system.
6.6.3 Immune isolation and drug release system.
6.6.4 Responsive drug delivery system.
6.6.5 Peptide & Protein Drug Delivery System.
Chapter 7: Analysis of Key Companies in China's Novel Formulation Industry.
7.1 Analysis of the operation of scientific research institutions in China's new preparation industry.
7.1.1 Analysis of the operation of the Institute of Materia Medica, Chinese Academy of Medical Sciences.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of the scientific research strength of enterprises.
4) Enterprise scientific research achievements and transformation.
5) Analysis of industry-university-research cooperation of enterprises.
6) Analysis of the advantages and disadvantages of the enterprise.
7) Analysis of the latest development trends of the enterprise.
7.1.2 Analysis of the operation of China Pharmaceutical Research and Development Center.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
7) Analysis of the latest development trends of the enterprise.
7.1.4 Analysis of the operation of Shanghai Research Institute of Pharmaceutical Industry.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of the scientific research strength of enterprises.
4) Enterprise scientific research achievements and transformation.
5) Cooperation between enterprises at home and abroad.
6) Analysis of the advantages and disadvantages of the company's operating conditions.
7) Analysis of the latest development trends of the enterprise.
7.1.5 Analysis of the operation of Beijing Boda Oasis Pharmaceutical Science and Technology Research.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of the scientific research strength of enterprises.
4) Enterprise scientific research achievements and transformation.
5) Enterprise strategic planning analysis.
6) Analysis of the advantages and disadvantages of the company's operating conditions.
7.1.6 Analysis of the operation of Tianjin Pharmaceutical Research Institute.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of the scientific research strength of enterprises.
4) Enterprise scientific research achievements and transformation.
5) Analysis of the industry-university-research situation of the enterprise.
6) Analysis of the advantages and disadvantages of the company's operating conditions.
7) Analysis of the latest development trends of the enterprise.
7.1.7 Analysis of the operation of North China Pharmaceutical Group New Drug Research and Development Co., Ltd.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of the scientific research strength of enterprises.
4) Enterprise scientific research achievements and transformation.
5) Analysis of the industry-university-research situation of the enterprise.
6) Analysis of the advantages and disadvantages of the company's operating conditions.
7) Analysis of the latest development trends of the enterprise.
7.1.8 Analysis of the operation of Guangzhou General Research Institute of Medicine.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of the scientific research strength of enterprises.
4) Enterprise scientific research achievements and transformation.
5) Analysis of industry-university-research cooperation of enterprises.
6) Analysis of the advantages and disadvantages of the enterprise.
7) Analysis of the latest development trends of the enterprise.
7.1.9 Analysis of the development of Sichuan Dianhong Pharmaceutical Development and Operation.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of the scientific research strength of enterprises.
4) Enterprise scientific research achievements and transformation.
5) Analysis of the advantages and disadvantages of enterprises.
7.1.10 Analysis of the operation of Tianjin Pharmaceutical Research Institute.
1) Brief analysis of enterprise development.
5) Enterprise sales channels and networks.
6) Analysis of business conditions.
1) Analysis of major economic indicators.
2) Analysis of the solvency of the enterprise.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
7) Analysis of the advantages and disadvantages of the company's operating conditions.
8) Analysis of the latest development trends of the enterprise.
7.2.2 Analysis of the business situation of Shandong Luye Pharmaceutical.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
4) Analysis of enterprise product structure.
5) Enterprise sales channels and networks.
6) Analysis of business conditions.
1) Analysis of major economic indicators.
2) Analysis of the solvency of the enterprise.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
7) Analysis of the advantages and disadvantages of the company's operating conditions.
8) Analysis of the latest development trends of the enterprise.
7.2.3 Analysis of the operation of Qingdao Huanghai Pharmaceutical Co., Ltd.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
4) Analysis of enterprise product structure.
5) Enterprise sales channels and networks.
6) Analysis of the advantages and disadvantages of the company's operating conditions.
7.2.5 Analysis of the operation of Sanofi Aventis (Hangzhou) Pharmaceutical.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
4) Analysis of enterprise product structure.
5) Enterprise sales channels and networks.
6) Analysis of business conditions.
1) Analysis of enterprise production and marketing capacity.
2) Analysis of the solvency of the enterprise.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
7) Analysis of the advantages and disadvantages of the company's operating conditions.
7.2.6 Analysis of the operation of Yabao Pharmaceutical Group's shares.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
9) Analysis of the latest development trends of the enterprise.
7.2.7 Yangtze River Pharmaceutical Group's business analysis.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
4) Analysis of enterprise product structure.
5) Enterprise sales channels and networks.
6) Analysis of business conditions.
1) Analysis of enterprise production and marketing capacity.
2) Analysis of the solvency of the enterprise.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
7) Analysis of the advantages and disadvantages of the company's operating conditions.
8) Analysis of the latest development trends of the enterprise.
7.2.8 Analysis of the operation of Sinopharm Guangdong Global Pharmaceutical.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
4) Analysis of enterprise product structure.
5) Enterprise sales channels and networks.
6) Analysis of business conditions.
1) Analysis of enterprise production and marketing capacity.
2) Analysis of the solvency of the enterprise.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
7) Analysis of the advantages and disadvantages of the company's operating conditions.
8) Analysis of the latest development trends of the enterprise.
7.2.9 Analysis of the operation of Shandong Zibo Xinda Pharmaceutical.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
4) Analysis of enterprise product structure.
5) Enterprise sales channels and networks.
6) Analysis of business conditions.
1) Analysis of enterprise production and marketing capacity.
2) Analysis of the solvency of the enterprise.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
7) Analysis of the advantages and disadvantages of the company's operating conditions.
8) Analysis of the latest development trends of the enterprise.
7.2.11 Analysis of the operation of Xi'an Janssen Pharmaceutical.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
4) Analysis of enterprise product structure.
5) Enterprise sales channels and networks.
6) Analysis of business conditions.
1) Analysis of enterprise production and marketing capacity.
2) Analysis of the solvency of the enterprise.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
7) Analysis of the advantages and disadvantages of the company's operating conditions.
8) Analysis of the latest development trends of the enterprise.
7.2.Analysis of the operation of 120,000 science and technology pharmaceuticals.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
4) Analysis of enterprise product structure.
5) Enterprise development strategy.
6) Analysis of business conditions.
1) Analysis of major economic indicators.
2) Analysis of the solvency of the enterprise.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
7) Analysis of the advantages and disadvantages of the company's operating conditions.
8) Analysis of the latest development trends of the enterprise.
7.2.13 Analysis of the operation of Zhejiang Jinhua Kangenbei Biopharmaceutical.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
4) Analysis of enterprise product structure.
5) Enterprise sales channels and networks.
6) Analysis of business conditions.
1) Analysis of major economic indicators.
2) Analysis of the solvency of the enterprise.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
7) Analysis of the advantages and disadvantages of the company's operating conditions.
8) Analysis of the latest development trends of the enterprise.
7.2.14 Analysis of the operation of Zhejiang Deer Pharmaceutical Co., Ltd.
1) Brief analysis of enterprise development.
2) Analysis of the main business of the enterprise.
3) Analysis of R&D strength of enterprises.
4) Analysis of enterprise product structure.
5) Enterprise sales channels and networks.
6) Analysis of business conditions.
1) Analysis of enterprise production and marketing capacity.
2) Analysis of the solvency of the enterprise.
3) Analysis of enterprise operation capabilities.
4) Enterprise profitability analysis.
5) Analysis of enterprise development ability.
7) Analysis of the advantages and disadvantages of the company's operating conditions.
Chapter 8: Development Trends and Investment Prospects of China's Novel Formulation Industry.
8.2.2 Barriers to entry in the industry.
1) Technical barriers.
2) R&D investment barriers.
3) Barriers to new drug approval.
4) Barriers to efficacy evaluation.
5) Barriers to auxiliary materials and equipment.
8.2.3 Analysis of industry profitability factors.
8.3 Investment analysis of China's new preparation industry.
Revenues (in billions of euros, %)
Exhibit 18: Key economic indicators of Sanofi-Aventis (in EUR billion), 2017-2023
Exhibit 19: Novartis Basic Information Table.
Exhibit 20: Novartis sales revenue from 2017 to 2023 (unit: US$ 100 million, %)
Exhibit 21: Novartis Key Economic Indicators (in USD billion), 2017-2023
Exhibit 22: Johnson & Johnson (Johnson & Johnson) Basics.
Exhibit 23: Sales revenue of Johnson & Johnson (JNJ) from 2017 to 2023 (unit: $100 million, %)
Exhibit 24: Johnson & Johnson's operating performance from 2017 to 2023 (in US$100 million).
Exhibit 25: 2017-2023 Abbott sales revenue (unit: US$ 100 million, %)
Exhibit 26: Analysis of Abbott's key economic indicators, 2017-2023 (in USD billion).
Exhibit 27: Schematic of the U.S. novel formulation market.
Figure 28: Ratio of common formulations to new formulations in the U.S. market (unit: %)
Figure 29: Examples of products jointly developed by patented drug companies and new drug companies.
Figure 30: Proportion of new drugs approved by FDA by type from 2017 to 2023.
Exhibit 31: Regulatory regime for the new formulation industry.
Exhibit 32: 2017-2023 new preparation industry policies at a glance.
Figure 33: Growth in consumption expenditure of urban and rural residents in China, 2017-2023 (unit: yuan).
Figure 34: Common disease occurrences (in %)
Figure 35: Disease Status in Major Cities (in %)
Figure 36: Statistics of total health expenditure of medical institutions in China from 2017 to 2023 (unit: 100 million yuan, %)
Figure 37: Growth rate of China's medical and health expenditure investment from 2017 to 2023 (unit: %)
Figure 38: Per capita health care expenditure of urban and rural residents, 2017-2023 (unit: yuan, %)
Figure 39: Production and sales scale and growth trend of the pharmaceutical industry from 2017 to 2023 (unit: 100 million yuan, %)
Figure 40: 2017-2023 pharmaceutical industry total industrial output value and growth rate trend (unit: 100 million yuan, %)
Figure 41: Trend of finished products and growth rate of the pharmaceutical industry from 2017 to 2023 (unit: 100 million yuan, %)
Exhibit 51: Analysis of the bargaining power of the new formulation industry.
Exhibit 52: Conclusion of the five forces analysis of the new formulation industry.
Figure 53: Some new formulations for oral administration abroad.
Exhibit 54: Nifedipine market distribution (in %)
Figure 55: Market demand analysis of new oral administration preparations from 2023 to 2031 (unit: 100 million yuan).
Figure 56: Some new formulations for injection administration abroad.
Figure 57: Distribution of osteoporosis drugs market in China (unit: %)
Exhibit 58: Calcitonin market distribution map (in %)
Figure 59: Market demand for new preparations for injection administration from 2023 to 2031 (unit: 100 million yuan).
Exhibit 60: Voglibose market distribution (in %)
Exhibit 61: Acarbose market distribution (in %)
Exhibit 62: Metformin film market distribution (in %)
Figure 63: Demand for Lung Drug Delivery Market 2023-2031 (Unit: 100 million yuan)
Figure 64: Some new formulations for transdermal administration abroad.
Figure 65: Market demand for transdermal new preparations from 2023 to 2031 (unit: 100 million yuan).
Exhibit 66: Classification of drug release systems.
Figure 67: Comparison of technical characteristics of several formulations.
Figure 68: Classification of drug release systems.
Figure 69: Global technology development for sustained-release formulations.
Figure 70: Development of sustained-release agent technology in China.
Figure 71: Classification of targeted agents.
Figure 72: Development of foreign targeted preparation technology.
Figure 73: Development of foreign targeted preparation technology.
Figure 74: Types of transdermal absorption promoters commonly used.
Figure 75 Types of accelerators in China.
Figure 76 Classification of mucosal drug delivery systems.
Figure 77: Classification of mucosal drug delivery systems.
Exhibit 74: Basic information table of the Institute of Materia Medica, Chinese Academy of Medical Sciences.
Figure 75: Brief analysis of the main business of the Institute of Materia Medica, Chinese Academy of Medical Sciences.
Exhibit 76: 2023 Innovative Drug List, Institute of Materia Medica, Chinese Academy of Medical Sciences.
Figure 77: Strengths and weaknesses of the Institute of Materia Medica, Chinese Academy of Medical Sciences.
Exhibit 78: Analysis of the advantages and disadvantages of China Pharmaceutical R&D Center.
Exhibit 79: Basic information table of Beijing Kexin Bicheng Pharmaceutical Technology Development.
Chart 80: Brief analysis of the main business of Beijing Kexin Bicheng Pharmaceutical Technology Development.
Chart 81: Brief analysis of the main business of Beijing Kexin Bicheng Pharmaceutical Technology Development.
Figure 82: Analysis of the advantages and disadvantages of Beijing Kexin Bicheng Pharmaceutical Technology Development.
Exhibit 83: Basic information table of Shanghai Research Institute of Pharmaceutical Industry.
Exhibit 84: Organizational chart of Shanghai Research Institute of Pharmaceutical Industry.
Figure 85: Winning projects of the National Technological Invention Award of Shanghai Institute of Pharmaceutical Industry.
Exhibit 86: Winning projects of the National Science and Technology Progress Award of Shanghai Institute of Pharmaceutical Industry.
Exhibit 87: Overview of domestic cooperative institutions of Shanghai Research Institute of Pharmaceutical Industry.
Figure 88: Overview of foreign cooperative institutions of Shanghai Institute of Pharmaceutical Industry.
Exhibit 89: Analysis of the advantages and disadvantages of Shanghai Institute of Pharmaceutical Industry.
Exhibit 90: Analysis of the advantages and disadvantages of Beijing Zhengda Oasis Pharmaceutical Technology.
Figure 91: Basic information table of Tianjin Institute of Materia Medica.
Figure 92: Organizational chart of Tianjin Institute of Materia Medica.